See the DrugPatentWatch profile for gilenya
Long-Term Safety of Gilenya
Gilenya, a medication used to treat multiple sclerosis (MS), has been on the market for over a decade.
What are the concerns about long-term use?
Some patients and researchers have raised concerns about the long-term effects of Gilenya, as it has been linked to potential side effects such as [1] increased risk of infections, [2] liver damage, and [3] macular edema (a condition that causes vision problems).
What does the manufacturer say about safety?
Novartis, the manufacturer of Gilenya, emphasizes that the medication has been extensively studied in clinical trials and has undergone rigorous testing for safety and efficacy [4]. According to the manufacturer, the benefits of Gilenya outweigh the risks for most patients with MS.
What do regulatory bodies say about safety?
The US FDA approved Gilenya for the treatment of relapsing forms of MS in 2010, with a required post-market surveillance program to monitor the medication's safety [5]. The European Medicines Agency (EMA) also approved the medication in 2010, noting that the risk of serious side effects is low [6].
Are there any long-term studies on Gilenya's safety?
While there are no long-term studies that have followed patients for 20 years or more, several trials have demonstrated the medication's safety over 5-7 years [7]. The manufacturer is currently conducting ongoing research to assess the long-term safety and efficacy of Gilenya.
Patient experiences and concerns
Patients taking Gilenya report varying levels of side effects, from mild to severe. Some have experienced serious side effects, such as increased risk of infections, but these events are rare [8]. Patients and their healthcare providers closely monitor the medication's effects to minimize risks.
Patent expiration and future developments
Gilenya's patent expires in [9]. As a result, biosimilars may enter the market in the near future, potentially increasing competition and lowering costs. Researchers continue to investigate new treatments for MS, which may provide patients with additional options.
References:
[1] https://www.drugpatentwatch.com/lookup/US7947258
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441457/
[3] https://www.ncbi.nlm.nih.gov/pubmed/29674019
[4] https://www.novartis.com/gilenya
[5] https://www.fda.gov/news-events/press-announcements/fda-approves-gilenya-reduce-frequence-relapses-multiple-sclerosis
[6] https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya
[7] https://www.ncbi.nlm.nih.gov/pubmed/29951467
[8] https://www.clinicaltrials.gov/ct2/show/NCT01700833
[9] https://www.drugpatentwatch.com/lookup/US7947258
Sources:
1. DrugPatentWatch.com
2. National Institutes of Health (NIH) Pubmed
3. Novartis website
4. US FDA press release
5. European Medicines Agency (EMA) website
6. ClinicalTrials.gov
7. National Institutes of Health (NIH) Pubmed